Literature DB >> 9870780

Protecting the viability of hepatic allografts procured from non-heart-beating donors by blockade of endothelin and platelet activating factor in porcine liver transplantation.

K Fukunaga1, Y Takada, H Taniguchi, K Yuzawa, M Otsuka, T Todoroki, K Goto, K Fukao.   

Abstract

PROBLEM: The function of hepatic allograft from non-heartbeating donors (NHBD) is significantly affected by warm ischemic injury before harvesting.
MATERIALS AND METHODS: The effects of the endothelin (ET) antagonist TAK-044 and the platelet activating factor (PAF) antagonist E5880 on the function of grafts from NHBD were evaluated in a porcine orthotopic liver transplantation. The liver grafts were subjected to 90 min of warm ischemia and 4 hours cold preservation. Group 1 (n = 4; n is the number of donor/recipient pairs) was used as a control (untreated). In group 2 (n = 4), donors and recipients were treated with TAK-044 (3 mg/kg). In group 3 (n = 4), pigs were treated with E5880 (0.3 mg/kg). In group 4 (n = 4), pigs were treated with TAK-044 and E5880.
RESULTS: The 7 day survival rate of the recipients in groups 1, 2, 3 and 4 was 0, 25, 25 and 100%, respectively (p<0.05, group 1 versus 4). The increases of the serum concentrations of aspartate transaminase, lactate dehydrogenase and arterial lactate 1-4 hours after transplantation were significantly inhibited in the treated groups.
CONCLUSION: The blockade of ET and PAF has protective effects on the function of hepatic grafts from NHBD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9870780

Source DB:  PubMed          Journal:  Int Surg        ISSN: 0020-8868


  1 in total

1.  Lipidomics comparing DCD and DBD liver allografts uncovers lysophospholipids elevated in recipients undergoing early allograft dysfunction.

Authors:  Jin Xu; Ana M Casas-Ferreira; Yun Ma; Arundhuti Sen; Min Kim; Petroula Proitsi; Maltina Shkodra; Maria Tena; Parthi Srinivasan; Nigel Heaton; Wayel Jassem; Cristina Legido-Quigley
Journal:  Sci Rep       Date:  2015-12-04       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.